Evidence map›Paper›PMID 39231221›Full record

ArticleScience advances2024

Nanoplasmonic aptasensor for sensitive, selective, and real-time detection of dopamine from unprocessed whole blood.

Aritra Biswas, Sang Lee, Pablo Cencillo-Abad, Manobina Karmakar, Jay Patel, Mahdi Soudi, Debashis Chanda

Abstract read
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aritra BiswasCREOL, The College of Optics and Photonics, University of Central Florida, 4304 Scorpius St., Orlando, FL 32816, USA.ORCID 0000-0002-9329-2684
Sang LeeNanoscience Technology Center, University of Central Florida, 12424 Research Parkway Suite 400, Orlando, FL 32826, USA.ORCID 0000-0001-8078-9088
Pablo Cencillo-AbadNanoscience Technology Center, University of Central Florida, 12424 Research Parkway Suite 400, Orlando, FL 32826, USA.ORCID 0000-0002-4118-1560
Manobina KarmakarNanoscience Technology Center, University of Central Florida, 12424 Research Parkway Suite 400, Orlando, FL 32826, USA.ORCID 0000-0002-9665-3203
Jay PatelNanoscience Technology Center, University of Central Florida, 12424 Research Parkway Suite 400, Orlando, FL 32826, USA.ORCID 0009-0000-0062-6087
Mahdi SoudiNanoscience Technology Center, University of Central Florida, 12424 Research Parkway Suite 400, Orlando, FL 32826, USA.ORCID 0009-0002-0858-8577
Debashis ChandaCREOL, The College of Optics and Photonics, University of Central Florida, 4304 Scorpius St., Orlando, FL 32816, USA.ORCID 0000-0002-4696-5436

Funding

NSF
6 · The paper itself

Abstract

Neurotransmitters are crucial for the proper functioning of neural systems, with dopamine playing a pivotal role in cognition, emotions, and motor control. Dysregulated dopamine levels are linked to various disorders, underscoring the need for accurate detection in research and diagnostics. Single-stranded DNA (ssDNA) aptamers are promising bioreceptors for dopamine detection due to their selectivity, improved stability, and synthesis feasibility. However, discrepancies in dopamine specificity have presented challenges. Here, we surface-functionalized a nano-plasmonic biosensing platform with a dopamine-specific ssDNA aptamer for selective detection. The biosensor, featuring narrowband hybrid plasmonic resonances, achieves high specificity through functionalization with aptamers and passivation processes. Sensitivity and selectivity for dopamine detection are demonstrated across a wide range of concentrations, including in diverse biological samples like protein solutions, cerebrospinal fluid, and whole blood. These results highlight the potential of plasmonic "aptasensors" for developing rapid and accurate diagnostic tools for disease monitoring, medical diagnostics, and targeted therapies.

Indexed as

Aptamers, NucleotideBiosensing TechniquesDNA, Single-StrandedDopamineHumansLimit of DetectionSurface Plasmon ResonanceAptamers, NucleotideDNA, Single-StrandedDopamine

Identifiers

PMID39231221
PMCPMC11373595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.